Ashvattha announced the presentation of a virtual poster supporting the development of its proprietary HDT, D-4517, for treatment of AMD at the 2021 ARVO Annual Meeting.
Ashvattha initiates a preclinical proof of concept study for OP-801 imaging of neuroinflammation. This Investigational New Drug (IND)-enabling research will be conducted in collaboration with a team of researchers at the Stanford University School of Medicine led by Michelle James, Ph.D., Assistant Professor of Radiology and Neurology.
Ashvattha Therapeutics announced data from a late-breaking presentation at The Liver Meeting Digital Experience 2020 of the American Association for the Study of Liver Diseases (AASLD), held virtually November 13-16, 2020.
Ashvattha announced the formation of a Scientific Advisory Board. The SAB will work closely with Ashvattha’s management team to select and develop highly differentiated HDTs to treat diseases with significant unmet medical need.
Ashvattha announced results from a preclinical study demonstrating the successful localization of HDs to target sites of inflammation in arthritic tissues at the ACR Convergence 2020, held virtually November 5-9, 2020.
Ashvattha announced results from a preclinical study demonstrating targeting of HDs to renal macrophages after acute ischemia in a diabetic animal model, at the American Society of Nephrology (ASN) Kidney Week 2020, held virtually October 19-25, 2020.
Ashvattha Therapeutics announced the appointment of George G. Montgomery to its board of directors. Montgomery brings more than 30 years of extensive experience as an investor, entrepreneur and investment banker across diverse healthcare sectors.
Jeffrey Cleland, Ph.D., chairman, chief executive officer and president of Ashvattha Therapeutics, will present at the virtual H.C. Wainwright 22nd Annual Global Investment Conference on Monday, September 14, 2020.
Orpheris, a subsidiary of Ashvattha, announced enrollment of the first patients in its multicenter Phase 2 PRANA clinical study of the HDT, OP-101, to treat hospitalized adults with severe COVID-19.
Orpheris, a subsidiary of Ashvattha, announced results from a Phase 1 single administration study evaluating the subcutaneous (SC) formulation of OP-101 (4 or 8 mg/kg) in healthy volunteers.